Mural Oncology plc (NASDAQ:MURA - Get Free Report) shot up 1.4% on Friday . The company traded as high as $3.64 and last traded at $3.62. 50,098 shares changed hands during trading, a decline of 69% from the average session volume of 162,563 shares. The stock had previously closed at $3.57.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th.
Get Our Latest Report on Mural Oncology
Mural Oncology Trading Up 4.7 %
The stock's 50 day moving average is $3.83 and its 200 day moving average is $3.58. The firm has a market cap of $64.68 million, a price-to-earnings ratio of -0.42 and a beta of 3.66.
Hedge Funds Weigh In On Mural Oncology
Large investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in Mural Oncology by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company's stock valued at $595,000 after buying an additional 4,731 shares in the last quarter. FMR LLC increased its position in Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company's stock worth $64,000 after acquiring an additional 11,423 shares during the period. Point72 Asset Management L.P. acquired a new stake in Mural Oncology in the 3rd quarter worth about $340,000. Commerce Bank bought a new stake in Mural Oncology in the 3rd quarter valued at about $39,000. Finally, Jane Street Group LLC acquired a new position in shares of Mural Oncology during the 4th quarter worth approximately $68,000. Institutional investors own 80.21% of the company's stock.
About Mural Oncology
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
